GC Biopharma Corp - Company Profile
Powered by 
All the sales intelligence you need on GC Biopharma Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how GC Biopharma Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with GC Biopharma Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
GC Biopharma Corp (GC Biopharma), formerly GC Pharma, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets plasma-derived products, including albumin, immunoglobulin, and antithrombin. It also produces vaccines to prevent infectious diseases and a portfolio of prescription medicines addressing cardiovascular, respiratory, central nervous system, gastrointestinal, immunology, musculoskeletal, genetic, metabolic, and hematological disorders. In the consumer health segment, GC Biopharma offers over-the-counter products such as anti-inflammatory medicines, anti-allergy treatments, and other self-care options. The company’s research and development activities focus on advancing new therapies for cancer, tuberculosis, and Hunter syndrome, as well as additional unmet medical needs. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.
GC Biopharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Prescription Drugs |
| Over-The-Counter Drugs |
| Quasi Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company partnered with the Korea Hemophilia Foundation and Seoul National University College of Pharmacy to develop an AI-based model predicting joint disease in hemophilia patients. |
| 2025 | Contracts/Agreements | In October, the company signed an agreement with Curevo Vaccine to manufacture recombinant shingles vaccine amezosvatein (CRV-101). |
| 2025 | Contracts/Agreements | In August, the company entered into a memorandum of understanding with the Thai Red Cross Society to work together on workforce training for the production of plasma-derived medicinal products. |
Competitor Comparison
| Key Parameters | GC Biopharma Corp | Yuhan Corp | Huons Global Co Ltd | Suheung Capsule Co Ltd | Jeil Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Yongin-si | Seoul | Seongnam | Cheongju | Seoul |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 2,355 | 1,594 | 541 | 727 | 978 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Il-sup Huh | Chairman; Chief Executive Officer | Executive Board | 2009 | 72 |
| Heo Eun-cheol | Chief Executive Officer; Director | Executive Board | - | 54 |
| Jeong Jae-wook | Director; Head - R&D Division | Executive Board | 2022 | 62 |
| Shin Woong | Director; Head - Quality Management | Executive Board | 2021 | 54 |
| Namkoong Hyun | Head - Marketing | Senior Management | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer